CTLA4 and nonpapillary renal cell carcinoma: Also, combination immune checkpoint blockade strategies (Concurrent PD‐1 and CTLA‐4 blockade using nivolumab plus ipilimumab) represent encouraging clinical benefits and have been authorized for the first‐line treatment of advanced/metastatic patients with ccRCC.28, 29